Mergers & acquisitions
As a valued member of our BioSpace community, we are eager to hear more from you and other readers in 2019. Let us know which topics you want to hear more about.
Yesterday, shareholders filed for a class action lawsuit against Tesaro in Delaware federal court, alleging that the merger is based on misleading financial analyses filed with the U.S. Securities and Exchange Commission (SEC).
Biotech and pharma companies came roaring out of the gate on the first day of the annual J.P. Morgan Healthcare Conference with big deals, expansions and promises of growth and pipeline sustainability.
In an interview with CNBC Monday, Novartis Chief Executive Officer Vas Narasimhan noted that the company is looking to become an entity that doesn’t draw its profits from treating disease, but will make money by providing cures.
Last year’s sole mega-deal, the acquisition of Dublin-based Shire by Japan-based Takeda Pharmaceutical is finally closed. Takeda, 237 years old, is now a top 10 international drug company.
Transaction Expected to Create NASDAQ-listed Biopharmaceutical Company Focused on Advancing Immunic‘s Compelling Pipeline of Clinical-Stage and Late Preclinical Assets
Eli Lilly and Company announced it was buying Loxo Oncology for $235 per share in cash, which comes to about $8 billion. The acquisition adds a lot of weight to Lilly’s oncology efforts.
- Company’s first foothold in the U.S.
Over the past decade, BMS has been no stranger to flexing its M&A muscle. The company made numerous focused-acquisitions that have positioned itself as a leader in oncology. BMS CEO Giovanni Caforio noted that the massive deal for Celgene is another piece to that puzzle.
Bristol-Myers Squibb will acquire Celgene Corporation to create a pharma giant with a significant pipeline focused on oncology, inflammatory and immunologic diseases, and cardiovascular disease.
PRESS RELEASES